Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

135 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Recurrent adamantinomatous craniopharyngiomas show MAPK pathway activation, clonal evolution and rare TP53-loss-mediated malignant progression.
Apps JR, Gonzalez-Meljem JM, Guiho R, Pickles JC, Prince E, Schwalbe E, Joshi N, Stone TJ, Ogunbiyi O, Chalker J, Bassey A, Otto G, Davies R, Hughes D, Brandner S, Tan E, Lee V, Hayhurst C, Kline C, Castellano S, Hankinson T, Deutschbein T, Jacques TS, Martinez-Barbera JP. Apps JR, et al. Among authors: hayhurst c. Acta Neuropathol Commun. 2024 Aug 10;12(1):127. doi: 10.1186/s40478-024-01838-4. Acta Neuropathol Commun. 2024. PMID: 39127699 Free PMC article.
De Novo Skull Base Atypical Meningioma: Incidence and Outcome.
James Z, Makwana M, Hayhurst C. James Z, et al. Among authors: hayhurst c. J Neurol Surg B Skull Base. 2022 Mar 8;84(2):113-118. doi: 10.1055/a-1757-3212. eCollection 2023 Apr. J Neurol Surg B Skull Base. 2022. PMID: 36895814 Free PMC article.
Delirium Prevention and Management in Frail Surgical Patients.
Rengel KF, Wahl LA, Sharma A, Lee H, Hayhurst CJ. Rengel KF, et al. Among authors: hayhurst cj. Anesthesiol Clin. 2023 Mar;41(1):175-189. doi: 10.1016/j.anclin.2022.10.011. Anesthesiol Clin. 2023. PMID: 36871998 Review.
Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study.
Liu Z, Le K, Zhou X, Alexander JL, Lin S, Bewshea C, Chanchlani N, Nice R, McDonald TJ, Lamb CA, Sebastian S, Kok K, Lees CW, Hart AL, Pollok RC, Boyton RJ, Altmann DM, Pollock KM, Goodhand JR, Kennedy NA, Ahmad T, Powell N; CLARITY study investigators. Liu Z, et al. Lancet Gastroenterol Hepatol. 2023 Feb;8(2):145-156. doi: 10.1016/S2468-1253(22)00389-2. Epub 2022 Dec 5. Lancet Gastroenterol Hepatol. 2023. PMID: 36481043 Free PMC article.
Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab.
Lin S, Kennedy NA, Saifuddin A, Sandoval DM, Reynolds CJ, Seoane RC, Kottoor SH, Pieper FP, Lin KM, Butler DK, Chanchlani N, Nice R, Chee D, Bewshea C, Janjua M, McDonald TJ, Sebastian S, Alexander JL, Constable L, Lee JC, Murray CD, Hart AL, Irving PM, Jones GR, Kok KB, Lamb CA, Lees CW, Altmann DM, Boyton RJ, Goodhand JR, Powell N, Ahmad T; CLARITY IBD study. Lin S, et al. Nat Commun. 2022 Mar 16;13(1):1379. doi: 10.1038/s41467-022-28517-z. Nat Commun. 2022. PMID: 35296643 Free PMC article.
135 results